Sign inCreate account

Report workspace tools

NCT01435629COMPLETEDanonymous

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Sponsor

Source record

Novo Nordisk A/S

Phase

Source record

Not classified

Modality

AI-normalized

small molecule

Target

AI-normalized

somatropin

Indication / condition

AI-normalized

Genetic Disorder

Intervention

Source record

somatropin

Source & freshness

Source record

NCT ID

NCT01435629

Original source

ClinicalTrials.gov

Source last updated

May 05, 2017

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01435629

Title

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Sponsor

Novo Nordisk A/S

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Genetic Disorder, Achondroplasia

Condition normalized

Genetic Disorder, Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

somatropin

Target normalized

somatropin

Interventions

somatropin

Public preview

Source record

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01435629

Status

COMPLETED

Phase

N/A

Sponsor

Novo Nordisk A/S

Executive brief

Investment-Ready Snapshot

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 05, 2017
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01435629

Indication

Genetic Disorder

Modality

small molecule

Target

somatropin

Intervention

somatropin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.